{"schema_version":"1","generated_at":"2026-10-29T07:30:50.997Z","data_as_of":null,"url":"https://www.findmykol.com/kol/linnea-chap","json_url":"https://www.findmykol.com/kol/linnea-chap/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"linnea-chap","name":"Linnea Chap","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"University of California, Los Angeles","institution_url":"https://www.findmykol.com/institution/university-of-california-los-angeles","city":"Beverly Hills","state":"CA","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1700839362","openalex":"A5038146265"},"summary":"Linnea Chap is an Oncology physician affiliated with University of California, Los Angeles. OpenAlex indexes 44 publications with 3,238 citations (h-index 16); ClinicalTrials.gov lists 5 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":44,"cited_by_count":3238,"h_index":16,"latest_activity_year":2025,"source":"works"},"trials":{"count":5,"shown":3,"withheld":2,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT00404404","title":"ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer","phase":"PHASE2","status":"UNKNOWN","role":"Overall official","sponsor":"Premiere Oncology","source_url":"https://clinicaltrials.gov/study/NCT00404404","trial_url":"https://www.findmykol.com/trial/NCT00404404"},{"nct":"NCT00378638","title":"Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study","phase":"PHASE2","status":"UNKNOWN","role":"Overall official","sponsor":"Chap, Linnea I., M.D.","source_url":"https://clinicaltrials.gov/study/NCT00378638","trial_url":"https://www.findmykol.com/trial/NCT00378638"},{"nct":"NCT00049244","title":"BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer","phase":"PHASE1","status":"UNKNOWN","role":"Overall official","sponsor":"R-Pharm","source_url":"https://clinicaltrials.gov/study/NCT00049244","trial_url":"https://www.findmykol.com/trial/NCT00049244"}],"source":"trials"},"payments":{"company_count":91,"program_years":{"first":2021,"last":null},"rows_total":174,"shown":3,"withheld":171,"rows":[{"payer":"PFIZER INC.","program_year":2025,"amount_usd":34440.47,"payment_count":25,"source_url":"https://openpaymentsdata.cms.gov/search?query=1700839362"},{"payer":"Daiichi Sankyo Inc.","program_year":2025,"amount_usd":14267.78,"payment_count":25,"source_url":"https://openpaymentsdata.cms.gov/search?query=1700839362"},{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":13326.82,"payment_count":33,"source_url":"https://openpaymentsdata.cms.gov/search?query=1700839362"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1700839362","source":"payments"},"funding":{"award_count":1,"fiscal_years":{"first":1999,"last":2001},"rows_total":4,"shown":3,"withheld":1,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"M01RR000865","title":"INTRAPERITONEAL IL 2 FOR EPITHELIAL OVARIAN CANCER W/ PATHOLOGICAL CR","fiscal_year":2001,"amount_usd":"207266","organization":"UNIVERSITY OF CALIFORNIA LOS ANGELES","source_url":"https://reporter.nih.gov/quickSearch/M01RR000865"},{"project":"M01RR000865","title":"INTRAPERITONEAL IL 2 FOR EPITHELIAL OVARIAN CANCER W/ PATHOLOGICAL CR","fiscal_year":2001,"amount_usd":"207266","organization":"UNIVERSITY OF CALIFORNIA LOS ANGELES","source_url":"https://reporter.nih.gov/quickSearch/M01RR000865"},{"project":"M01RR000865","title":"INTRAPERITONEAL IL 2 FOR EPITHELIAL OVARIAN CANCER W/ PATHOLOGICAL CR","fiscal_year":1999,"organization":"UNIVERSITY OF CALIFORNIA LOS ANGELES","source_url":"https://reporter.nih.gov/quickSearch/M01RR000865"}],"source":"grants"},"publications":{"total":43,"shown":5,"withheld":38,"matched_by":"OpenAlex author record","recent":[{"title":"Body mass index as a predictive factor for efficacy of adjuvant taxane‐based chemotherapy in early‐stage breast cancer patients: A pooled analysis from adjuvant <scp>GEICAM</scp> Spanish Breast Cancer Group and <scp>TRIO</scp> Translational Research in Oncology Group studies","year":2025,"journal":"International Journal of Cancer","source_url":"https://doi.org/10.1002/ijc.35432","status":"verified"},{"title":"Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib","year":2025,"journal":"Nature Communications","source_url":"https://doi.org/10.1038/s41467-025-57535-w","status":"verified"},{"title":"Abstract P3-11-10: Benefit/risk relationship of TCH versus AC-TH in BCIRG 006: analysis using generalized pairwise comparisons","year":2025,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1557-3265.sabcs24-p3-11-10","status":"verified"},{"title":"Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials","year":2025,"journal":"The Oncologist","source_url":"https://doi.org/10.1093/oncolo/oyaf263","status":"verified"},{"title":"Abstract PO1-03-03: STEEP criteria v2.0 validation: A multi-trial analysis using GEICAM and TRIO adjuvant trials to evaluate surrogate endpoints for overall survival","year":2024,"journal":"Cancer Research","source_url":"https://doi.org/10.1158/1538-7445.sabcs23-po1-03-03","status":"verified"}],"source":"works"},"contact":{"address_1":"8900 WILSHIRE BLVD","city":"Beverly Hills","state":"CA","zip":"902111958","phone":"310-432-8900","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1700839362","source":"identity"},"similar":[{"name":"Dennis Slamon","slug":"dennis-slamon","institution":"University of California, Los Angeles","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/dennis-slamon","json_url":"https://www.findmykol.com/kol/dennis-slamon/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"},{"name":"Richard Casaburi","slug":"richard-casaburi","institution":"University of California, Los Angeles","specialty":"Pulmonary Disease","url":"https://www.findmykol.com/kol/richard-casaburi","json_url":"https://www.findmykol.com/kol/richard-casaburi/profile.json"},{"name":"Jerome Engel","slug":"jerome-engel","institution":"University of California, Los Angeles","specialty":"Neurology","url":"https://www.findmykol.com/kol/jerome-engel","json_url":"https://www.findmykol.com/kol/jerome-engel/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":2,"payments":171,"funding":1,"publications":38}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2014-03-25","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}